Hyrimoz (adalimumab-adaz) / Sandoz - LARVOL DELTA

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. (PubMed, Saudi Pharm J) - "Patients received various adalimumab products, including the reference biologic (Humira, 70.7%) and biosimilars (Amgevita, 16.2%; Hyrimoz, 13.1%). No significant differences in clearance were observed, suggesting comparable clearance. The adoption of biosimilars in clinical practice could improve patient access to biologic therapies while substantially reducing healthcare costs."

Journal • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025) (ISPOR 2026) - "Other biosimilars, such as Amjevita (~10% share) and Hadlima (~2% share), showed moderate uptake, while Simlandi and Hyrimoz represented a negligible portion of Medicaid reimbursement during this period. Medicaid biosimilar adoption is accelerating but follows a unique product selection trajectory distinct from major commercial PBM trends. Medicaid biosimilar adoption is accelerating but follows a unique product selection trajectory distinct from major commercial PBM trends. The significant expenditure share of Cyltezo in FFS programs suggest successful state-level or Medicaid-specific contracting strategies that differ from the broader market. These findings highlight the importance of using expenditure-based metrics over volume-based metrics when analyzing Medicaid claims to avoid artifacts from unit-of-measure discrepancies."

Medicaid • Reimbursement • US reimbursement

Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial. (PubMed, Immunotherapy) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Effectiveness and safety of adalimumab biosimilar in bio-naive patients with inflammatory bowel disease: a real-life multicenter observational study comparing ABP501, SB5, MSB11022, GP2017, and FKB327. (PubMed, Crohns Colitis 360) - "Furthermore, there is no significant difference between the 5-ADA biosimilars. Drug persistence was significantly higher in patients with CD treated with IMM and with post-induction ADA levels ≥7 μg/mL."

Journal • Observational data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Major U.S. Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing. (PubMed, Arthritis Care Res (Hoboken)) - "While biosimilar adalimumab prescriptions rose sharply after a major national formulary change, the increase was not sustained. These findings highlight that persistent barriers, including the nocebo effect and the administrative burden of switching, may continue to limit biosimilar adoption and contribute to the loss of substantial cost savings in the US market."

Journal • Rheumatology

Safety and Effectiveness of Multi-Switch between Adalimumab Originator and Biosimilars in Inflammatory Bowel Disease: A Multicenter (SUSTAIN) Study (ECCO-IBD 2026) - "Adult patients receiving adalimumab-adaz, or adalimumab-atto were included. Conclusion Multiple switches of adalimumab biosimilars can be safely undertaken without increasing the risk of adverse reactions, or treatment failure. Our study provides meaningful evidence to guide policy, resource allocation, and clinician confidence in biosimilar interchangeability as a sustainable therapeutic strategy in IBD mansagement."

Clinical • Immunology • Inflammation • Inflammatory Bowel Disease

Possible Involvement of β1-Adrenoceptors in the Positive Chronotropic Effects of Mirabegron. (PubMed, Biol Pharm Bull) - "Isoproterenol (0.1-100 nM), a nonselective β-adrenoceptor agonist, dobutamine (0.001-100 μM), a β1-adrenoceptor agonist, and salbutamol (0.001-100 μM), a β2-adrenoceptor agonist, induced concentration-dependent positive chronotropic effects, with the potency order of isoproterenol > dobutamine > mirabegron ≥ salbutamol in mice, and isoproterenol > dobutamine ≥ salbutamol > mirabegron in guinea pigs. Conversely, the selective β1-adrenoceptor antagonist CGP20172A (0.03-3 nM) strongly and non-competitively antagonized mirabegron-induced positive chronotropic effects in mouse and guinea pig atria. These results suggest that the positive chronotropic effects of mirabegron are primarily mediated through β1-adrenoceptors, with minimal or no involvement of β2- and β3-adrenoceptors."

Journal • Overactive Bladder

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. (PubMed, J Clin Med) - "Adult patients receiving adalimumab-adaz or adalimumab-atto were included. Multiple switches of adalimumab biosimilars can be safely undertaken without increasing the risk of adverse reactions or treatment failure. This study provides meaningful evidence to guide policy and physician confidence in biosimilar interchangeability as a sustainable IBD therapeutic strategy."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report. (PubMed, SAGE Open Med Case Rep) - "A 34-year-old woman with psoriasis and psoriatic arthritis developed acquired perforating dermatosis after switching from adalimumab biosimilar GP2017-CTP17...Both conditions were later managed with methotrexate and ixekizumab...Early recognition and discontinuation may prevent progression. Further studies are needed to clarify pathogenesis."

Journal • Cognitive Disorders • Dermatology • Diabetes • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies

O05 A retrospective review of cases of psoriasis requiring discontinuation of biologic therapy from 2007 to 2024 in a multisite NHS trust. (PubMed, Br J Dermatol) - "Concurrent systemic immunosuppression (methotrexate or ciclosporin) was prescribed in 21% (n = 31)...The biologics with most interventions were adalimumab or biosimilars (n = 102: Humira n = 39, Idacio n = 30, Hyrimoz n = 23, Amgevita n = 10), ustekinumab (n = 39), secukinumab (n = 35), guselkumab (n = 13) and certolizumab (n = 11)...The main blood abnormality was positive tuberculosis ELISpot assay (interferon-γ release assay) (n = 6: Humira n = 2; and Idacio, ustekinumab, etanercept and risankizumab n = 1 each). Other abnormalities included leucocytosis in sepsis (n = 2; ustekinumab, secukinumab), neutropenia (n = 1; Hyrimoz), raised alanine aminotransferase (n = 1; Humira) and raised fetal calprotectin (n = 1; Ixekizumab)...Blood abnormalities requiring treatment intervention were infrequent, most commonly positive tuberculosis testing. Our findings support reducing blood monitoring of..."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Neutropenia • Pain • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • Seronegative Spondyloarthropathies • Tuberculosis • Type 2 Diabetes Mellitus • Ulcerative Colitis • Urticaria • IFNG

HYRISS: Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting (clinicaltrials.gov) - P=N/A | N=562 | Active, not recruiting | Sponsor: Sandoz | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Anti-Tumor Necrosis Factor-Associated IgAN (KIDNEY WEEK 2025) - "On Humira since 2017, switched to Hyrimoz in 2024, with no Crohn’s flares since 2017...Anemic (Hb 10 g/dL) with worsening microscopic hematuria and new proteinuria (2g/g, improved to 1.3g/g with Lisinopril)...Infliximab has also been known to cause IgA Nephropathy in patient with Pustular Psoriasis as well as Ankylosing Spondylitis. It is important for a patient treated with Adalimumab for Crohn's Disease to have frequent follow ups with their renal function tests to monitor for TNF alpha inhibitor induced renal dysfunction, early diagnosis and treatment of which can be life saving."

Ankylosing Spondylitis • Back Pain • Chronic Kidney Disease • Crohn's disease • Dermatology • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lumbar Back Pain • Musculoskeletal Pain • Nephrology • Oncology • Pediatrics • Psoriasis • Pustular Psoriasis • Renal Disease • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TNFA

Price Behavior of Originator Adalimumab After Biosimilars Entry: Evidence From the Colombian Market (ISPOR-EU 2025) - "Biosimilars (Amgevita®, Idacio®, and Hyrimoz®) were included from their respective market entry dates. Prices of originator adalimumab declined steadily after biosimilar entry, with similar trends observed for biosimilars. These findings suggest that biosimilar competition contributes to cost containment and plays a key role in improving access and promoting sustainability within the colombian health system."

Real World Rate of Efficacy of Adalimumab Biosimilars Following a Mandated Switch in an Academic Medical Center (ACR Convergence 2025) - "Rheumatoid arthritis was the most common diagnosis (32.1%) Across the 18-month time period, 97 patients (9.6%) were switched to a biosimilar with adalimumab-adaz and adalimumab-bwwd most common. Real world experience following mandated switch from adalimumab to a biosimilar showed a marginally higher rate of discontinuation than comparable cohorts from outside the United States. The cost of medication saved by switching to biosimilar medications may justify this rate of unanticipated mediation interruption."

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after (ACR Convergence 2025) - "CVS Caremark removed adalimumab from its national formulary in favor of adalimumab-adaz in April 2024. The CVS formulary change had a dramatic effect on prescriptions. The increase started 2 months before the official date, which likely reflects proactive changes in ordering practices by clinicians and pharmacists. The large decrease immediately after the formulary change has not been reported elsewhere."

Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Nurses' perceptions on the usability of the Hyrimoz® Sensoready® autoinjector device. (PubMed, Drugs Context) - "Visual feedback and buttonless activation were the main qualitative features driving this overall preference. Gastroenterology nurses in the USA expressed strong preferences for the Hyrimoz Sensoready pen versus the Humira pen when rating each device individually, and in direct quantitative and qualitative comparisons."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study. (PubMed, BMC Immunol) - "The number of flares before and after switching to Hyrimoz was comparable. However, adverse effects and increased subjective complaints have been reported after switching to this new biosimilar."

Journal • Retrospective data • Immunology • Inflammation • Pain

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy. (PubMed, Dermatol Reports) - "The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies."

Journal • Dermatology • Immunology • Psoriasis • TNFA

Retention rate of adalimumab bio-original and biosimilars in rheumatic diseases: a real world study from the Hong Kong Biologics Registry (EULAR 2025) - "boADA (Humira) accounted for 1185 and bsADA (Amgiveta or Hyrimoz) accounted for 1411 courses. The retention rate of bsADA appears to be higher than that of boADA in the treatment of inflammatory arthritis in our registry, which was mainly driven by data from patients with RA and SpA. Caution must be undertaken for interpretation of the results because the follow-up period of the bsADA was significantly shorter. A longer period of observation is necessary."

Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Dermatology • Hepatology • Infectious Disease • Inflammatory Arthritis • Liver Failure • Oncology • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars. (PubMed, Biosensors (Basel)) - "AAA interacted with Humira®, Hyrimoz®, and Imraldi® with similar apparent affinity (10-9 M > KD > 10-10 M); slight variations have been observed among patients, less among biosimilars. The similarity in KD values across biosimilars and the originator supports the notion that, at the level of immunogenicity, biosimilars can be considered clinically comparable to the originator."

Journal • Idiopathic Arthritis • Immunology • Pediatrics • Rheumatology

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes. (PubMed, Reumatismo) - "In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings."

Journal • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study. (PubMed, Biologics) - "The biosimilars were ABP 501 (85%), GP2017 (14%), SB5 (1%); 41 (32%) patients switched from originator. Estimated cost savings were 5,030€ per patient/year. This real-life study demonstrated high durability and remission rates for adalimumab biosimilars in PIBD, confirming their clinical, cost-effectiveness and safety profile in children."

HEOR • Journal • Real-world evidence • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Inflammation • Inflammatory Bowel Disease • Lymphoma • Oncology • Pediatrics • Psoriasis • Ulcerative Colitis

Efficacy, Immunogenicity and Safety of Various Biosimilar Tumor Necrosis Factor Inhibitors in Ocular inflammatory diseases (ARVO 2025) - "Ten patients were on adalimumab biosimilars (6 Hyrimoz, 2 Hadlima, 1 Cyltezo, 1 Amjevita), and one was on infliximab biosimilar (Inflectra). Describe the big picture and the implications of your findings, not the study itself and the associated details. This study assesses the efficacy, immunogenicity and safety of tumor necrosis factor inhibitor biosimilars in ocular inflammatory disease, to evaluate their potential as a more affordable alternative to reference products and broaden access to biologics."

Clinical • Ocular Inflammation • Ophthalmology • Uveitis

Sandoz reports strong FY 2024 results and Q4 2024 sales (GlobeNewswire) - "Net sales for the fourth quarter were USD 769 million, up 25% in constant currencies. Net sales for the full year were USD 2.9 billion, up 30% in constant currencies. The biosimilars share of total net sales increased from 23% in FY 2023 to 28% in FY 2024. The strong double-digit biosimilars growth reflects the uptake of Hyrimoz in the US through the private- label agreement with...the Sandoz Hyrimoz and unbranded adalimumab-adaz. In addition...the continued strong demand for the first-ever biosimilar...and the launches of Tyruko and Pyzchiva in Europe all contributed to the strong performance."

Sales • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease • Ophthalmology • Rheumatoid Arthritis

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study. (PubMed, Acta Derm Venereol) - "When comparing GP2017 and SB5, no discernible differences were found in drug survival or effectiveness based on PASI. Determining drug survival and effectiveness could benefit patients and clinicians in treatment decisions."

Clinical • Journal • Real-world evidence • Retrospective data • Dermatology • Immunology • Psoriasis